Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Echinocandins are the first-line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once-weekly intravenous administration, offering potential advantages in complex clinical settings. OBJECTIVES: We aimed to describe our real-world experience with rezafungin for the treatment of invasive fungal disease (IFD). PATIENTS: A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted. RESULTS: We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical intervention (38.5%). Most frequent Candida species were C. albicans (38.5%), C. parapsilosis (30.8%) and Nakaseomyces glabratus (15.4%). One patient had necrotizing gingival infection due to Trichoderma longibrachiatum. Main types of IFD included intravascular Candida infection (38.5%) and surgical-site and intra-abdominal candidiasis (23.1% each). Reported reasons for initiating rezafungin were the presence of fluconazole-resistant isolates (53.8%), facilitating outpatient antifungal therapy (30.8%) and avoiding anticipated drug-drug interactions with triazoles (15.4%). No patient received rezafungin as a first-line treatment and most (92.3%) had been previously exposed to other echinocandins. Rezafungin was typically initiated upon clearance of follow-up blood cultures (80.0%). Median number of weekly doses was 4.0 (interquartile range: 3.0-5.5). Clinical cure (complete or partial response) by day +30 was achieved in all evaluable patients (100.0% [12/12]), with no treatment-emergent adverse events. CONCLUSIONS: Rezafungin was effective and safe as salvage or consolidation therapy in patients with IFD, including deep-seated candidiasis.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice
- Date Crossref
- 01/02/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Instituto de Salud Carlos III pays non établi dans la noticeOrganisation à but non lucratif
-
Research Institute Hospital 12 de Octubre pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario 12 De Octubre pays non établi dans la noticeÉtablissement de santé
-
Centro de Investigación Biomédica en Red pays non établi dans la noticeStructure de recherche
-
Centro de Investigación Biomédica en Red Enfermedades Infecciosas pays non établi dans la noticeStructure de recherche
-
Universidad Complutense de Madrid pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Universidad Complutense Madrid Spain pays non établi dans la noticeUniversité ou école supérieure
Instituto de Salud Carlos III, Research Institute Hospital 12 de Octubre et Hospital Universitario 12 De Octubre, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.